|
Actualités & Communiqués de Presse |
|
2008 January |
|
|
Meet us at the AACR International Conference 'Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic' (January 22-25, 2008; San Diego, CA). Our abstract has been selected for an oral presentation that will be given during the session 'Ubiquitin, transcription and epigenetics' scheduled for 4:00 p.m. - 5:00 p.m. on Thursday, January 24. |
|
|
13 December 2007 |
|
Paris, 13 December 2007 – Hybrigenics and L’Oréal are working together to know more about certain kin and hair proteins and to discover innovative substances: following the discovery of new interactions between skin proteins, a chemical screening has been carried out to identify small molecules able to inhibit one of these interactions, as part of L'Oréal's scientific research for innovative cosmetics.
|
|
|
2007 October |
|
|
Meet us at the AACR-NCI-EORTC International Conference ‘Molecular Targets and Cancer Therapeutics’ (October 22-27, 2007 * San Francisco, CA) during the Poster session ‘Other Small Molecule Therapeutic Agents’ (Abstract # C220) on Thursday, October 25 from 12:30 to 7:30PM. |
|
|
2007 April |
|
Hybrigenics’ inecalcitol shows high level of tolerance
Paris, April 12, 2007- Hybrigenics successfully performs first clinical trial -Hybrigenics announces today the first results from its Phase I clinical trial of inecalcitol, a synthetic analogue of vitamin D under development by Hybrigenics as a potential treatment for prostate cancer.
|
|
|
2007 February |
|
Hybrigenics focuses its research on inhibitors of ubiquitin-specific proteases in cancer Dutch subsidiary sells non-core research patents
Paris, February 20, 2007 - Hybrigenics announces today that it is concentrating its research efforts on ubiquitin-specific proteases (USPs) and their inhibitors in cancer. Consequently, Hybrigenics has divested the patent portfolio of Semaia, its Dutch subsidiary, on the Wnt-pathway and the EPAC targets. |
|
|
2006, August |
|
Hybrigenics appoints Dr Bernhard Ehmer to its Board of Directors
Paris, August 1, 2006 - Hybrigenics, the protein pathway-based cancer drug discovery and development company, announces today the appointment of Bernhard R M Ehmer, MD, to its supervisory board as a non-executive independent Director. Dr Ehmer, CEO of BioPheresis Technologies, brings 20 years of
clinical R&D and business management experience from the pharma industry
|
|
|
2006 February |
|
Hybrigenics acquires worldwide rights to inecalcitol, a vitamin D analogue
Paris, February 7, 2006. - Hybrigenics SA announced that it has acquired a license for the worldwide exclusive rights to inecalcitol, a synthetic analogue of vitamin D, for all clinical indications. Hybrigenics intends to focus on an oral formulation to develop inecalcitol in cancer indications, such as advanced androgen-independent prostate cancer, and expects this acquisition to rapidly move its R&D pipeline towards clinical development. |
|
|
2005 December |
|
Hybrigenics provides protein interaction screening and analysis tools for Genethon’s muscle cell program
2005 December - Hybrigenics, the pathway-based drug discovery company, today announces that Genethon, the gene and cell therapy research and application center, will use Hybrigenics’ Yeast Two-Hybrid Screening platform and its Protein Interaction Mapping software in a new program of research into muscle cell proteins and their interaction. The program will allow a better understanding of the muscle and the development of new therapeutic leads. |
|
|
2005, November |
|
Hybrigenics names new CEO and Board Chairman
Paris, November 8, 2005—Hybrigenics, the protein pathway based drug discovery company, today announces the appointments of Rémi Delansorne as Chief Executive Officer, and Daan Ellens as Chairman of the Board. The appointments follow the death earlier this year of Bart Kwist, president and CEO. |
|
|
2005 May |
|
Hybrigenics obtains worldwide certification for its proteomics services
2005 May - Hybrigenics, the protein pathway based drug discovery company, has obtained worldwide quality certification for its proteomics services. These include the coveted ISO 9001-2000 European certification, the QMI in the USA and the JQA in Japan. |
|
|
2005 May |
|
NiKem Research Srl and Hybrigenics SA Significantly Expand their Research Service Agreement in the Oncology Area
Milan and Paris— May 10th, 2005 - NiKem Research Srl and Hybrigenics SA announced today that they have expanded and extended a Research Service Agreement already in place between the two companies. Under the terms of the agreement, NiKem will continue using its medicinal chemistry platform and expertise to optimize inhibitors of Ubiquitin Specific Proteases (USP) as new therapeutic agents against cancer. This family of proteases has been the focus of thorough target identification and validation studies by Hybrigenics in the field of Oncology. |
|
|
2005 February |
|
A protein interaction map for a better insight in cancer development
2005 February - With the completion of the genome sequence of a number of organisms, analysis of the gene products, the proteins, is the on-going challenge. Researchers from the Institut Curie and from the Paris-based biotechnology company Hybrigenics announced today that they have built a protein-protein interaction map of the fruit fly, Drosophila melanogaster. This ‘simple’ model organism allows them to study a ‘reference set’ of proteins that includes most of those known to be involved in human cancer. Since proteins function in networks, the systematic identification of the physical interactions that occur between proteins will help understanding their biological function, and improve our capacity to intervene and, ultimately, to discover novel, more specific therapeutic targets. Their results are published in the March 1st issue of Genome Research. |
|
| << Start < Prev 1 Next > End >>
| | Results 1 - 13 of 13 |
|
|
|
|
